newsfilter
← Latest News
GlobeNewswire·

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross proceeds